EUVIMEDEUVIMED entdecken
Open Access

CD24 is a novel target of chimeric antigen receptor T cells for the treatment of triple negative breast cancer

Peiwei Yang, Fan Yu, Zheng Yao, Xu Ding, Hanmei Xu, Juan Zhang

Cancer Immunology, Immunotherapy · 2023

DOI: 10.1007/s00262-023-03491-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2023. Verfasst von Peiwei Yang und 5 weiteren Autor:innen. Beteiligte Einrichtung: The Engineering Research Center of Synthetic Polypeptide Drug Discovery and Evaluation, China Pharmaceutical University, Nanjing, 210009, Jiangsu Pro…. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Fundamental Research Funds for the Central Universities, the Project Program of State Key Laboratory of Natural Medicines, the National Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple negative breast cancer (TNBC) is a subtype of breast cancer with the highest degree of malignancy and the worst prognosis. The application of immunotherapy for TNBC is limited. This study was to verify the potential application of chimeric antigen receptor-T cells (CAR-T cells) targeting CD24 named as 24BBz in treatment of TNBC. 24BBz was constructed by lentivirus infection and then was co-culture with breast cancer cell lines to evaluate the activation, proliferation and cytotoxicity of engineered T cells. The anti-tumor activity of 24BBz was verified in the subcutaneous xenograft model of nude mice. We found that CD24 gene was significantly up-regulated in breast cancer (BRCA), especially in TNBC. 24BBz showed antigen-specific activation and dose-dependent cytotoxicity against CD24-positive BRCA tumor cells in vitro. Furthermore, 24BBz showed significant anti-tumor effect in CD24-positive TNBC xenografts and T cells infiltration in tumor tissues, while some T cells exhibited exhaustion. No pathological damage of major organs was found during the treatment. This study proved that CD24-specific CAR-T cells have potent anti-tumor activity and potential application value in treatment of TNBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenTriple Negative Breast NeoplasmsAnimalsMiceHumansMice, NudeT-LymphocytesImmunotherapyCell Line, TumorCD24 Antigen

Stichwörter der Autor:innen

CAR-T cell therapyCD24 antigenSolid tumorTNBC

Substanzen

Receptors, Chimeric AntigenCD24 protein, humanCD24 Antigen

Autor:innen und Institutionen

  • The Engineering Research Center of Synthetic Polypeptide Drug Discovery and Evaluation, China Pharmaceutical University, Nanjing, 210009, Jiangsu Province, People's Republic of China.
  • State Key Laboratory of Natural Medicines, Ministry of Education, China Pharmaceutical University, 639 Longmian Avenue, Jiangning District, Nanjing City, 210009, Jiangsu Province, People's Republic of China.
  • Nanjing Anji Biological Technology Co., LTD, Nanjing, 210033, People's Republic of China.
  • Department of Oral and Maxillofacial Surgery, Affiliated Hospital of Stomatology, Nanjing Medical University, Nanjing, 210029, People's Republic of China.
  • The Engineering Research Center of Synthetic Polypeptide Drug Discovery and Evaluation, China Pharmaceutical University, Nanjing, 210009, Jiangsu Province, People's Republic of China. xuhanmei6688@126.com.
  • State Key Laboratory of Natural Medicines, Ministry of Education, China Pharmaceutical University, 639 Longmian Avenue, Jiangning District, Nanjing City, 210009, Jiangsu Province, People's Republic of China. xuhanmei668…

Förderung

  • Fundamental Research Funds for the Central Universities
  • the Project Program of State Key Laboratory of Natural Medicines
  • the National Natural Science Foundation

Zitieren

APA

Yang, P., Yu, F., Yao, Z., Ding, X., Xu, H., & Zhang, J. (2023). CD24 is a novel target of chimeric antigen receptor T cells for the treatment of triple negative breast cancer. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-023-03491-7

Vancouver

Yang P, Yu F, Yao Z, Ding X, Xu H, Zhang J. CD24 is a novel target of chimeric antigen receptor T cells for the treatment of triple negative breast cancer. Cancer Immunology, Immunotherapy. 2023. doi:10.1007/s00262-023-03491-7

BibTeX
@article{Yang2023,
  author = {Yang, Peiwei and Yu, Fan and Yao, Zheng and Ding, Xu and Xu, Hanmei and Zhang, Juan},
  title = {CD24 is a novel target of chimeric antigen receptor T cells for the treatment of triple negative breast cancer},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2023},
  doi = {10.1007/s00262-023-03491-7}
}
Kostenlos starten →